The Casey Eye Institute is honored to be able to serve the vision care needs of the citizens of the Pacific Northwest. As we pursue the missions of service to our community, education of providers, cutting edge clinical care, and groundbreaking research, CEI has developed many unique programs. We will highlight a few of these in this year’s annual report.

Casey has developed several public health programs that are particularly noteworthy. This year, in partnership with the Oregon State Elks and Head Start, we were successful in providing preschool vision screening to thousands of Oregon’s children. We plan to extend screening for eye diseases to the adult population, with the deployment of a fully equipped vision screening vehicle. Remarkably, failure of adult patients to receive timely intervention is the principal cause of permanent vision loss in patients with diabetes, macular degeneration, and glaucoma, the leading causes of blindness in the U.S. Our pediatric and adult populations continue to be served by the Evelyn L. Jones Low Vision Rehabilitation Center. This clinic partners with our Macular Degeneration Center in producing the Low Vision Expo, the largest patient symposium in the Pacific Northwest specifically addressing needs of patients with vision loss.

Increasingly, Casey is being recognized as a national leader in research. The Inflammatory Eye Disease Group’s research has led to the approval of a new agent for the treatment of inflammation inside the eye that has fewer side effects.

The Retina Research Group has initiated the use of gene therapy and cell-based therapy in the treatment of inherited retinal disease. Several exciting trials are underway coordinated through the newly created Translational Clinical Trials Center. The Glaucoma Research Group continues to do pioneering work on intraocular pressure, and how elevated pressure damages the optic nerve.

Casey’s successful programs provide incredibly fertile ground for the training of scientists and health care professionals. We have seen continued growth in the numbers of ophthalmologists in training, and have now added international fellowships as part of the WHO organization’s efforts to eliminate preventable blindness by year 2020.

Our annual report is being produced in an electronic format that will be accessible on Casey’s new website, due to launch late this summer. The new website will provide a complete resource for patients, providers and supporters to follow the many activities that occur throughout the year.

With warm regards,

David J. Wilson, M.D.
Thiele-Petti Chair, Department of Ophthalmology
Director, Casey Eye Institute, OHSU
Portland and surrounding area

Casey faculty provided free vision screening to homeless diabetics at Outside In, a social service agency in downtown Portland. Fundraising is also underway for a mobile vision screening and treatment van to reach underserved populations at risk for glaucoma, diabetic retinopathy and other treatable eye diseases.

Oregon

Thousands of preschoolers throughout Oregon received free vision testing through the Elks Children’s Eye Clinic’s nationally-recognized program. The screenings provide early detection of such vision problems as amblyopia, which can lead to permanent impairment if not treated before age five.
Pacific Northwest

Last October, patients, family members and health professionals from throughout the region learned about the latest advances in research, treatment and low vision care at the Macular Degeneration and Low Vision Expo in Portland. The free program, sponsored by Casey’s Macular Degeneration Center and Evelyn L. Jones Low Vision Rehabilitation Center, featured talks by Casey faculty Michael Klein, M.D., and John Boyer, O.D. and workshops led by the Oregon Commission for the Blind. Guest speaker Renee Bove’ brought a message of hope as she described how her own vision loss led to a new life of travel and humanitarian work with the help of visual aids. An exhibit area featured demonstrations of assistive devices and information about programs and services for sight-impaired individuals.

“For not only was the expo a unique educational experience, it offered the emotional support of others who share the same challenges,” says Dr. Boyer.

The World

Casey’s commitment to improving eye health on a global level remains strong. Kevin Winthrop, M.D., M.P.H., and Devin Gattey, M.D., continue to focus on eradication of river blindness, a sight-robbing parasitic eye disease prevalent in Central and South America. The two regularly travel to this region to conduct epidemiology studies and train other health professionals in the diagnosis and treatment of this disease. Winthrop and Gattey also spearhead an international fellowship program to train foreign physicians in special skills for use in their home countries. Casey’s international ophthalmology fellows in 2008 were Maria Sanchez, M.D., from Guatemala and Belen Morales, M.D., from Ecuador. This summer, Joao Furtado, M.D., will arrive from Brazil.

For information about the next Macular Degeneration and Low Vision Expo slated for May 2010, contact Joan Kahn at 503 494-3537 or email kahnj@ohsu.edu
David Wilson, M.D., Chairman of the Department of Ophthalmology is very excited about the impact this center will have on eye disease. “We will have all of the tools to customize diagnostic tests, build a special database to document results and develop a uniform grading system to regulate test quality.” The customized diagnostic testing includes capturing eye structures with photographic images, mapping eye nerve health with visual fields and evaluating visual function with electroretinograms. With the ability to gather and analyze test data, the Casey Reading Center will be able to initiate and oversee clinical trials. In this leadership role, the Reading Center will certify other clinical sites across the country and ensure that each center adheres to the same strict protocol in testing patients and recording results.
Initial Focus on Retinal Diseases
Initially, the Casey center will focus on retinal diseases including retinitis pigmentosa, Stargardt macular dystrophy and age-related macular degeneration which are all characterized by progressive photoreceptor loss and decreased vision.

Gene Therapy
Researchers know that replacing the defective genes with healthy ones might halt vision loss and possibly even restore vision. However, gene therapy is a complex process. It involves identifying the correct target gene and delivering replacement genetic material into the cell with the objective of restoring healthy functioning. Recently, Casey researchers (Principal Investigator: Dr Tim Stout, M.D., Ph.D.) have embarked on their first gene therapy trial to treat Leber Congenital Amaurosis. The gene therapy is being tested in a Phase I clinical trial on 12 people. Results will be analyzed at the reading Center.

Cell-Based Therapy
Another therapy emerging from research involves the delivery of cells into the retina to either replace lost tissue or to prevent further degeneration. In collaboration with several academic and commercial partners, Casey researcher Raymond Lund, Ph.D. working with Peter Francis, M.D. Ph.D., has successfully transplanted cells into animal models of retinal degeneration with most encouraging results. This research has formed the basis for another Phase I clinical trial being conducted by the center (Principal Investigator: Peter Francis, M.D. Ph.D.). Nine patients with advanced retinitis pigmentosa are receiving cells that have the potential to restore healthy functioning and Dr Francis is excited about this and other upcoming trials. “For the first time, we may have the ability to offer something specific to help repair the damage from these rare inherited retinal diseases and possibly reverse devastating vision loss.”

For further information about current and future clinical trials, please contact Andrea Bauman-Carnegie, Ph.D. at 503 418-3216 or email baumana@ohsu.edu
# Faculty

## Comprehensive Ophthalmology
- Kelly Chung, M.D.
- Rebecca Armour, M.D.
- William Farr, M.D.
- Devin Gattey, M.D.
- Tammie Krisciunas, O.D., M.Ed.
- Malcolm Marquis, M.D.

## Cornea, External Disease and Refractive Surgery
- Larry Rich, M.D.
- Frederick T. Fraunfelder, M.D.
- Frederick W. Fraunfelder, M.D.
- William Mathers, M.D.
- Rachael Garrett, O.D.
- Derek Louie, M.Sc., O.D.
- Winston Chamberlain, M.D.
- Mauricio Cabezas, M.D. (fellow)
- Anand Shah, M.D. (fellow)

## Glaucoma
- John Morrison, M.D.
- Beth Edmunds, M.D., Ph.D.
- Ted Acott, Ph.D.
- Elaine Johnson, Sc.D.
- Mary Kelley, Ph.D.
- Mary Wirtz, Ph.D.
- Zakary Hoffelt, M.D. (fellow)
- Michael Lloyd, M.D. (fellow)

## International Ophthalmology
- Kevin Winthrop, M.D., M.P.H.
- Devin Gattey, M.D.

## Low Vision Rehabilitation
- John Boyer, O.D.
- Jill Scheiffele, O.D.

## Neuro-ophthalmology
- Julie Falardeau, M.D.
- William Hills, M.D., O.D.

## Ophthalmic Genetics/Retinal Dystrophies
- Richard Weleber, M.D.
- Peter Francis, M.D., Ph.D.
- Mark Pennesi, M.D., Ph.D. (fellow)

## Ophthalmic Plastic and Reconstructive Surgery
- Roger Dailey, M.D.
- John Ng, M.D., M.S.
- Eric Steele, M.D.
- Mauricio Chavez, M.D. (fellow)

## Pediatric Ophthalmology and Adult Strabismus, Elks Children’s Eye Clinic
- Daniel Karr, M.D.
- Laurie Christensen, M.D.
- Leah Reznick, M.D.
- Ann Stout, M.D.
- Earl Palmer, M.D.
- Mike Powers, M.D.
- David Wheeler, M.D.
- Allison Summers, O.D.
- Kevin Merrill M.D. (fellow)

## Retina and Vitreous Disease and Surgery
- Andreas Lauer, M.D.
- Christina Flaxel, M.D.
- Peter Francis, M.D., Ph.D.
- Thomas Hwang, M.D.
- Michael Klein, M.D.
- Joseph Robertson, M.D., M.B.A.
- J. Timothy Stout, M.D., Ph.D., M.B.A.
- Robert Watzke, M.D.
- David Wilson, M.D.
- Binoy Appukuttan, Ph.D.
- Alvin Eisner, Ph.D.
- Raymond Lund, Ph.D.
- Catherine Morgans, Ph.D.
- Dennis Schultz, Ph.D.
- Rowland Taylor, Ph.D.
- Steven Bailey, M.D.
- Brian Chan-Kai, M.D. (fellow)
- Rob Witherspoon, M.D. (fellow)
- Jacob Jones, M.D., Ph.D. (fellow)
- Steven Yeh, M.D. (fellow)

## Uveitis
- James Rosenbaum, M.D.
- Justine Smith, M.B.B.S., Ph.D.
- Eric Suhler, M.D., M.P.H.
- Ellen Lee, O.D., Ph.D.
- Tammy Martin, Ph.D.
- Stephen Planck, Ph.D.
- Shelly Lee, M.D. (fellow)
- Seema Gupta, M.D. (fellow)

# Residents

## Director:
- Andreas K. Lauer, M.D.

## Associate directors:
- Rebecca L. Armour, M.D.,
- Devin M. Gattey, M.D., and
- Thomas Hwang, M.D.

### First Year (2008-2011)
- Rebekah Allen, M.D.
  - University of New Mexico 2007
- Ellen Davis, M.D.
  - OHSU 2007
- Lani Hoang, M.D.
  - OHSU 2007
- Naveen Rao, M.D.
  - Baylor 2007
- Justin Wilkinson, M.D.
  - UCSF 2007

### Second Year (2007-2010)
- Dinelli Monson, M.D.
  - University of Wisconsin 2006
- Dilsher Dhoot, M.D.
  - OHSU 2006
- Michael Page, M.D.
  - University of Michigan 2006
- Angela Watkins, M.D.
  - OHSU 2006

### Third Year (2006-2009)
- David Dance, M.D.
  - Baylor 2005
- Lorinna Lombardi, M.D.
  - Stanford 2005
- Amanda Richards, M.D.
  - University of South Dakota 2005
- Shad Saunders, M.D.
  - Wake Forest University 2005
**Awards**

**Grazyna Adamus, Ph.D.** served on the REAP External Advisory Board at the Portland VA Medical Center and is a member of the Gene and Drug Delivery Systems Study Section.

**Boyer, John, O.D.** was asked by Wilmer Eye Institute, Johns Hopkins University to join a consortium of low vision clinics and participate in a multi-center national pilot study leading to a randomized clinical trial that will evaluate the effectiveness of low vision services. Dr. Boyer was honored by the Oregon Commission for the Blind with their 2008 Community Service Award.

**Dongseok Choi, Ph.D.** received the 2008 Chapter Service Recognition Award from the American Statistical Association (ASA). The ASA is the largest statistical association and the 2nd oldest professional association in the USA.

**Roger Dailey, M.D.** received the AAO Secretariat Award from the American Academy of Ophthalmology. Other awards Dr. Dailey received in 2008 included the Robert Kennedy Presidential Award from the American Society of Ophthalmic Plastic and Reconstructive Surgeons, and the Orkan G. Stasior, M.D. Leadership Award from the American Society of Ophthalmic Plastic and Reconstructive Surgeons.

**Christina Flaxel, M.D.** received the Faculty Member of the Year Award from the Casey Eye Institute in 2008. Dr. Flaxel was nominated to the American Ophthalmological Society (AOS) and was an invited speaker at the World Ophthalmology Congress in June, 2008.

**Rick Fraunfelder, M.D.** was nominated to the American Ophthalmological Association and is the president elect of the International Society of Ocular Toxicology, as well as the Head of the Ocular Toxicology section of International Society of the Ocular Pharmacology and Therapeutics.

**Dan Karr, M.D.** served as education chairman for the American Academy of Pediatrics Executive Committee (Ophthalmology Section) and as vice chairman, Fellowship Training Compliance Committee, American Association for Pediatric Ophthalmology and Strabismus.

**Mike Klein, M.D.** was honored by the Oregon Commission for the Blind with their 2008 Community Service Award. Dr. Klein was elected incoming president of the Macula Society, an international organization of retinal clinicians and researchers.

**John Morrison, M.D.** received the Research to Prevent Blindness Senior Investigator Award and was selected Fellow of ARVO.

**John Ng, M.D.** was a featured invited speaker for Tanta University’s Annual International Conference of Advanced Ophthalmology in Tanta, Egypt. Dr. Ng was appointed as Secretary of Meetings for the American Society of Ophthalmic Plastic, Orbital and Reconstructive Surgery, Chair of the Joint Symposium of AAO and American Society of Ocularists.

**Steve Planck, Ph.D.** was on the Eye Injury peer review panel for grants submitted to the Department of Defense Congressionally Directed Medical Research Programs.

**James Rosenbaum, M.D.** served as a full time member of the NIH anterior eye disease study section and a full time member of the NIH Board of Scientific Counselors. He was been awarded the American Academy of Ophthalmology lifetime achievement award. Dr. Rosenbaum was invited to speak for the Costa Rican Rheumatology Society, the Pan American League Against Rheumatism, Seoul National University, the Panama Rheumatology Society, the Saudi Ophthalmology Society, the International Society for Ophthalmic Pharmacology, and the Ghent Ankylosing Spondylitis Biannual Meeting. Dr. Rosenbaum gave the featured talk at the annual Canadian Ophthalmology Society Meeting. He is program chair for the American Uveitis Society ARVO meeting and serves on the Harvard Advisory Board for its NIH sponsored ophthalmology training grant. Dr. Rosenbaum has been appointed to the National Eye Institute Advisory Council Planning Oversight Subcommittee.

**Justine Smith, M.B.B.S., Ph.D.** was co-author on two papers that were judged by an international committee of judges to be the best experimental or clinical papers in the field of uveitis in the preceding year. Dr. Smith gave invited talks at the 2008 AAO meeting subspecialty day and at the ARVO sponsored symposium. She served as invited faculty at the 3rd Annual Heed Ophthalmic Foundation Resident's Retreat in Denver, Colorado. Dr. Smith serves as a member of the International Council: International Ocular Inflammation Society, is a member of the international jury committee for the Cora Verhagen Prize; is a member of the Executive Committee (AAO Education Liaison) and is a member of the Specialty Information Team (Uveitis) AAOO. She served
as a co-organizer of the ARVO Summer Conference on Ocular Autoimmunity and Inflammation in Monterey, CA. Dr. Smith serves on several pharmaceutical advisory boards, editorial boards and was elected as a Trustee for ARVO.

Allison Summers, O.D. was asked to be on the work group for HB 2060 and HB 2064, the proposed children’s vision legislation for Oregon.

Eric Suhler, M.D., M.P.H. was nominated by the American Uveitis Society for a spot in the American Academy of Ophthalmology’s Leadership Development Program. For over seven years Dr. Suhler has been requested to direct a day of lectures in UT-Houston’s yearly Basic and Clinical Sciences series on uveitis. He has been invited to lecture at the International Society on Ocular Pharmaceuticals and Therapeutics in Rome, Italy.

William Taylor, Ph.D. was an invited speaker at the XVIII International Congress for Eye Research, Beijing, China and is a member of the editorial board for Visual Neuroscience.

Kevin Winthrop, M.D., M.P.H. was actively involved in a number of international initiatives including: Agency for Healthcare Research and Quality (AHRQ) – adverse drug event surveillance and prevention; Oxford Immunotec – diagnostic assay development for mycobacterial infections; Carter Center – development of assays to detect River Blindness; and, Carter Center of the Americas – new therapeutic strategies for River Blindness in the Americas.

David Wilson, M.D. was elected to the Council for the American Ophthalmological Society and serves as a Trustee for the Heed Foundation.


Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 28(4):606-9, 2008 Apr.


<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Project Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ted Acott</td>
<td>NEI</td>
<td>The vertebrate eye: studies of aqueous outflow</td>
</tr>
<tr>
<td>Grazyna Adamus</td>
<td>NEI</td>
<td>Mechanism of retinal damage in autoimmune retinopathy</td>
</tr>
<tr>
<td>Elaine Johnson</td>
<td>NEI</td>
<td>The optic nerve head in glaucoma</td>
</tr>
<tr>
<td>Kate Keller</td>
<td>GRF</td>
<td>RNAi gene silencing of enzymes in the glycosaminoglycan biosynthetic pathway</td>
</tr>
<tr>
<td>Mary Kelley</td>
<td>GLPRF</td>
<td>Development of a Novel Glaucoma Treatment from Stem Cell Stimulation</td>
</tr>
<tr>
<td>Michael Klein</td>
<td>NEI</td>
<td>Genetics of age-related macular degeneration</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Comparison of Age-Related Macular Degeneration Treatments Trial (CATT)</td>
</tr>
<tr>
<td>GenVec</td>
<td>PBA</td>
<td>Molecular Markers of Trabecular Meshwork Stem Cells</td>
</tr>
<tr>
<td>Andy Lauer</td>
<td>NEI</td>
<td>Laser-ranibizumab-triamcinolone for DME study</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Laser-ranibizumab-triamcinolone for PDR study</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Laser response study</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Triamcinolone acetone vs. laser for diabetic macular edema</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Vitrectomy for diabetic macular edema</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>SCORE - Standard care vs. corticosteroid for retinal vein occlusion</td>
</tr>
<tr>
<td>Ellen Lee</td>
<td>NEI</td>
<td>In vivo imaging of corneal inflammation</td>
</tr>
<tr>
<td>Gerling</td>
<td>NEI</td>
<td>Leukocyte adhesion and migration within the inflamed cornea</td>
</tr>
<tr>
<td>Bin Lu</td>
<td>CMT</td>
<td>Stem/Progenitor Cell Therapy for Macular Dystrophy. HSH-Cell-Based Therapies for Usher Syndrome.</td>
</tr>
<tr>
<td>Raymond Lund</td>
<td>FFB</td>
<td>Cell-based therapies and alternative growth factor delivery approaches on retinal organization and visual function</td>
</tr>
<tr>
<td>FFB</td>
<td></td>
<td>Customized IPS Cell Therapy for Recessive Monogenic Retinal Degenerative Disease.</td>
</tr>
<tr>
<td>Stem Cell</td>
<td></td>
<td>Stem cells for retinal degeneration: preliminary efficacy study.</td>
</tr>
<tr>
<td>Tammy Martin</td>
<td>NEI</td>
<td>Uveitis Gene-Expression Profiling</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Analysis of genetic susceptibility to anterior uveitis</td>
</tr>
<tr>
<td>William Mathers</td>
<td>OHSUF</td>
<td>High throughput screening of transcription factor activity</td>
</tr>
<tr>
<td>OHSUF</td>
<td></td>
<td>Risks of laser surgery versus contacts</td>
</tr>
<tr>
<td>OHSUF</td>
<td></td>
<td>Acanthamoeba keratitis</td>
</tr>
<tr>
<td>Catherine Morgans</td>
<td>NEI</td>
<td>Calcium Channels at Ribbon Synapses in the Retina</td>
</tr>
<tr>
<td>OHSUF</td>
<td></td>
<td>Presidential Bridge Funding Grant</td>
</tr>
<tr>
<td>John Morrison</td>
<td>NEI</td>
<td>Studies in glaucomatous optic nerve damage</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Non-invasive pressure measurements in rodents</td>
</tr>
<tr>
<td>Alcon</td>
<td></td>
<td>Rat glaucoma model development</td>
</tr>
<tr>
<td>RPB</td>
<td></td>
<td>Senior scientific investigator award</td>
</tr>
<tr>
<td>Mark Pennesi</td>
<td>FFB</td>
<td>Career Development Award</td>
</tr>
<tr>
<td>Jim Rosenbaum</td>
<td>NEI</td>
<td>Chemotactic factors in animal models of uveitis</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Ophthalmology core grant module</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Four-dimensional imaging of immune response in vivo</td>
</tr>
<tr>
<td>NEI</td>
<td></td>
<td>Uveitis gene-expression profiling</td>
</tr>
<tr>
<td>Allergan</td>
<td></td>
<td>Posurdex for anterior uveitis</td>
</tr>
<tr>
<td>Allergan</td>
<td></td>
<td>Posurdex for intermediate uveitis</td>
</tr>
<tr>
<td>Funding Source</td>
<td>Project/Program</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td><strong>Allergan</strong></td>
<td>Posurdex for posterior uveitis</td>
<td></td>
</tr>
<tr>
<td>GNT</td>
<td>Rituximab in refractory scleritis and orbital inflammation</td>
<td></td>
</tr>
<tr>
<td>RPB</td>
<td>Senior scientific investigator award</td>
<td></td>
</tr>
<tr>
<td>Vertex</td>
<td>T cell/B cell interactions in a mouse model of EAE</td>
<td></td>
</tr>
<tr>
<td><strong>Mary Wirtz</strong></td>
<td>Biophysical limitations to signal transmission in the mammalian retina</td>
<td></td>
</tr>
<tr>
<td>Lincy</td>
<td>Cell-based therapies and alternative growth factor delivery</td>
<td></td>
</tr>
<tr>
<td><strong>Holly Rosenzweig</strong></td>
<td>Investigation of NOD2: implications for uveitis (NRSA Fellowship Award)</td>
<td></td>
</tr>
<tr>
<td><strong>Dennis Schultz</strong></td>
<td>Characterization of 10q26 AMD Protein</td>
<td></td>
</tr>
<tr>
<td><strong>Justine Smith</strong></td>
<td>Novel Molecular Regulators of Choroidal Neovascularization in Age-Related Macular Degeneration</td>
<td></td>
</tr>
<tr>
<td>IRRF</td>
<td>Molecular Mediators of Proliferative Diabetic Retinopathy</td>
<td></td>
</tr>
<tr>
<td>HSH/FFB</td>
<td>Clinical trials infrastructure</td>
<td></td>
</tr>
<tr>
<td>Ntech</td>
<td>ECT CNTF for retinitis pigmentosa</td>
<td></td>
</tr>
<tr>
<td><strong>Tim Stout</strong></td>
<td>Gene therapy for Leber's congenital amaurosis</td>
<td></td>
</tr>
<tr>
<td>AGTC</td>
<td>EyeGate iontophoresis for anterior uveitis study</td>
<td></td>
</tr>
<tr>
<td>Celegene</td>
<td>Apremilast for refractory uveitis</td>
<td></td>
</tr>
<tr>
<td>LuxBio</td>
<td>LUMINATE: LX211 for posterior uveitis (01)</td>
<td></td>
</tr>
<tr>
<td>LuxBio</td>
<td>LUMINATE: LX211 for quiescent uveitis (02)</td>
<td></td>
</tr>
<tr>
<td>LuxBio</td>
<td>LUMINATE: LX211 for anterior uveitis (03)</td>
<td></td>
</tr>
<tr>
<td>Abbott</td>
<td>Humira for uveitis</td>
<td></td>
</tr>
<tr>
<td><strong>David Wheeler</strong></td>
<td>Validation of the Molecular Test for Predicting Metastasis in Patients with Uveal Melanoma</td>
<td></td>
</tr>
<tr>
<td><strong>Kevin Winthrop</strong></td>
<td>Adverse drug event surveillance and prevention</td>
<td></td>
</tr>
<tr>
<td><strong>WU</strong></td>
<td>Diagnostic assay development for mycobacterial infections</td>
<td></td>
</tr>
<tr>
<td><strong>AC</strong></td>
<td>Adverse sequelae of biologic immunosuppressive therapies</td>
<td></td>
</tr>
<tr>
<td><strong>Carter</strong></td>
<td>Development of assays to detect River Blindness infection</td>
<td></td>
</tr>
<tr>
<td><strong>Carter</strong></td>
<td>New therapeutic strategies for River Blindness in the Americas</td>
<td></td>
</tr>
</tbody>
</table>

**KEY**

**Federal Funding**
- **NEI** National Eye Institute, National Institutes of Health
- **AHRQ** Agency for Healthcare Research and Quality
- **AHAF** American Health Assistance Foundation

**Foundation Funding**
- **Carter** Carter Center
- **CMT** Collins Medical Trust
- **FFB** Foundation Fighting Blindness
- **Gerling** Gerlinger Research Fund
- **GFF** Glaucoma Research Foundation
- **GLPRF** Gustavus and Louise Pfeiffer Research Foundation
- **HSH** Hear See Hope Foundation
- **IRRF** International Retina Research Fund
- **Lincy** Lincy Foundation
- **NNRI** National Neurovision Research Institute
- **OHSUF** Oregon Health & Science Foundation
- **PBA** Prevent Blindness America
- **RBP** Research to Prevent Blindness
- **SCO** The Society for Clinical Ophthalmology
- **WU** Washington University

**Pharmaceutical Funding**
- **Abbott** Abbott Laboratories
- **Alcon** Alcon, Inc.
- **AGTC** Applied Genetic Technologies Corporation
- **Allergan** Allergan, Inc.
- **Celegene** Celegene Corporation
- **EyeGate** EyeGate Pharma
- **GenVec** GenVec Inc.
- **GNT** Genentech
- **LuxBio** Lux Biosciences
- **Ntech** Neurotech Pharmaceuticals, Inc.
- **Othera** Othera Pharmaceuticals Inc.
- **Oxford** Oxford Immunotec
- **Sirion** Sirion Therapeutics
- **Stem Cell** Stem Cells, Inc.
- **UCB** UCB Pharma
- **Vertex** Vertex Pharmaceuticals
Casey Eye Institute has been fortunate to receive generous funding from our loyal patients and friends. Philanthropic gifts that come to the Oregon Health & Science University Foundation are vital to moving forward with groundbreaking treatments and first rate patient care.

Anonymous (7)
Aetna Foundation Matching Gift Program
Aetna Foundation, Inc.
Mr. & Mrs. Philip D. Aines
Allergan, Inc.
Mr. & Mrs. Kermit S. Alsok
Ms. Nancy L. Andersen
Mr. & Mrs. Ernest L. Anderson
Ankrom Moisan Associated Architects
Mrs. Shanti M. Armstrong
Mr. Michael W. Bannon
Mr. Joseph M. Barkofski
William H. Bauman & Mary L. Bauman Foundation
Ms. Shirley A. Baumgardner
Mr. & Mrs. Harold J. Beal
Mr. & Mrs. John R. Bell
Ms. Barbara Benninghoff
Lucille Jerree Berg Trust Estate
Mr. & Mrs. Morris H. Bergman
Ms. Eileen R. Blaser
Mr. Ernest J. Blatner
Blount, Inc.
Charlotte Ann Thomson Borgen Estate
Dr. Rodney V. Both
John M. Boyer, D.O.
Mr. & Mrs. William M. Bresley
Ms. Barbara D. Briller
Broughton & Mary Bishop Family Fund of CFSWW, Inc.
Ms. Rebecca R. Brown
Mr. Shawn L. Brown
Mr. Mark Bruso
Mr. & Mrs. Mark L. Bubenik
Buckaroo-Thermoseal, Inc.
Mr. Richard J. Bucolo
Ella Munro Burdin Fund of the OCF
Ms. Dorothea L. Burke
Mr. & Mrs. Robert J. Burns
Mr. & Mrs. Robert C. Button
Campbell Wallace Foundation
Dr. & Mrs. Wiley L. Campbell, ’55
Milton & Cissi Carl Fund of the OJCF
Ms. Jacqueline T. Carver
Maureen D. Casey
Mr. & Mrs. Leonard L. Cebula
Alan L. Chaimov, M.D. & Mrs. Anne Chaimov
Mr. & Mrs. Donald J. Chambers
Mr. & Mrs. Virgil H. Chandler
Mr. & Mrs. Alan F. Charles
Alyce R. Cheatham Fund of the OCF
Laurie E. Christensen, M.D., ’82 & Colin Ma, M.D.
Mr. & Mrs. T. W. Churchill
Mr. & Mrs. Leslie L. Clark
Mr. & Mrs. Malcolm N. Clark
Maybelle Clark Macdonald Fund
Mike & Tracey Clark
Mr. & Mrs. Judson B. Clifton
Mrs. Brita L. Clothier
Mrs. Nina J. Combest
Mr. & Mrs. Terrill F. Cox
Ms. Rosemary H. Crowder
Ms. Jeanne M. Damon
Dano Law Firm
Dr. & Mrs. James Rodney Delp, ’65
Delta Gamma Foundation
Denisa C. Jennison Trust
Mr. Hershel Dennis
Mr. & Mrs. Richard S. Dorr
Dortha F. Luke Estate
Mr. & Mrs. Gerald L. Dotson
Mr. Paul M. Dudley
Julie R. Durand, M.D. & Larry J. Durand, D.M.D.
Emory University
Ericksen Foundation
Richard Estey
Evergreen International Aviation

SOURCES OF GIFT INCOME 2008

- CORPORATIONS/FOUNDATIONS/ORGANIZATIONS (61%) $2,750,253.51
- ESTATES (26%) $1,176,389.52
- INDIVIDUALS (12%) $515,221.20
- ALUMNI (1%) $43,708.90
- OTHER (0%) $1,415.00

TOTAL = $4,486,988.10

DESIGNATION OF GIFT INCOME 2008

- CURRENT OPERATIONS $4,070,484.48 (91%)
- ENDOWMENT $371,549.71 (8%)
- QUASI-ENDOWMENT $26,060.00 (1%)
- CAPITAL $18,893.92 (0%)

TOTAL = $4,486,988.10
“I thoroughly enjoy supporting Casey. It is a wonderful organization that is made up of talented people that truly care for their patients. From the time I walk in the doors, the staff and doctors make the experience so comfortable – what can I say, it feels like family!”  

- Dick Estey
June M. Lloyd Trust
Mr. Frank G. Long
Jonathan Madrigano
Mr. & Mrs. Edward L. Maletis
Mr. & Mrs. Greg A. Mamula
Mr. & Mrs. Robert P. Manley
Mary’s Woods
Dr. Joseph D. Matarazzo &
Dr. Ruth G. Matarazzo
Mr. & Mrs. Leslie E. Matson, Jr.
Ms. Patricia A. McCracken
Ms. Diana T. McCluskey
Ms. Virginia M. McConnaughy
Mr. & Mrs. Roger K. McDonald
Ms. Elizabeth A. McDowell
McGraw Family Foundation, Inc.
Nancie S. McGraw
Mr. Timothy H. McNees &
Ms. Sandy L. Eng
Mr. & Mrs. Daniel F. McNeil
Mr. & Mrs. J. P. Meng
Ms. Lillian Meyers
Mr. Fred D. Miller &
Ms. Karla J. Wenzel
Mr. & Mrs. Richard H. Miller
Mrs. H. H. Minthorn
Mr. & Mrs. Wayne A. Moreland
Mr. & Mrs. Stephen M. Morelli
Mr. George P. Moriarty
Mr. & Mrs. Todd H. Morrison
John C. Morrison, M.D., ’77 & Lynne
H. Morrison, M.D., ’82
Ms. Marilyn L. Morrison
Ms. Cecile Musselman
Mrs. Patricia A. Muth
Samuel T. & Mary K. Naito Foundation
Mr. & Mrs. Louis Nadell
V. Nelson
Mr. & Mrs. Marvin S. Nepom
Newmark Family Fund of the OJCF
Jeanne & Herb Newmark
Mr. & Mrs. Gib Nichols
Northwest Christian Community Foundation
Novartis US Foundation
Robert H. Noyes, Jr.
Mr. Michael Nyland
Mr. Ernest M. Ogard, Jr.
Mr. & Mrs. Michael Z. Olds
Ms. Helen N. Olson
Oregon State Elks Association Visual Committee
Mr. & Mrs. Gary Oshiro
Mr. & Mrs. Laimons Osis
Mrs. Susan F. Osterman
Pamplin Foundation Paper Products Marketing
Mario & Alma Pastega Family Foundation
Mr. & Mrs. Stuart Patterson
Mr. & Mrs. John S. Patterson
Joseph M. Pelz, D.M.D. &
Mrs. Cheryl A. Pelz
Mr. & Mrs. Douglas L. Peterson
Mr. & Mrs. Wallace W. Phillips, Jr.
Sandy & Harvey Platt
Mr. & Mrs. Wilson G. Plummer
Portland Oculoplastics, P.C.
Preston H. Orem Estate
Ms. Alice L. Price
Dr. & Mrs. Paul J. Puffer, ’63
Mr. & Mrs. James J. Raggio
Mr. & Mrs. Russel Z. Railsback
Mr. & Mrs. William L. Reagan
Red Dog Investments, LLC
Regence Employee Giving Campaign
Mr. Emler H. Renken
Research to Prevent blindness
Jeanne Schnitzer Reynolds
Larry F. Rich, M.D., ’70
Robert L. & Marilyn Ridgley
RingSide Steakhouse
Mr. & Mrs. Bruce E. Ritchie
Mr. & Mrs. George D. Rives
Robert C. & Nani S.
Warren Foundation
Gayle & Paul Romain
Dr. James T. Rosenbaum &
Dr. Sandra J. Lewis
D. Rosencrantz Family Fund of the OJCF
Stanley & Madelle Rosenfeld Family Fund of the OJCF
Robert C. Rosenquist, Jr., M.D. &
Mrs. Linda Rosenquist
Mrs. Editha Rowell
Ms. Elvira Sagatelian
Mr. & Mrs. Jon A. Salquist

“I support the institute because I want to honor my husband’s legacy, Dr. Peter Rowell, who did his residency program at the Department of Ophthalmology and became a wonderful product of the school.”

- Editha Rowell
“Giving to Casey returns a triple bonus on every dollar: Casey’s clinicians, teachers and researchers provide patients with expert care, train future physician leaders and apply leading edge research to solving the most perplexing issues in ophthalmology.”

- Bob Ridgley

Names followed by an asterisk (*) indicate deceased donors. We have endeavored to make this list as accurate and complete as possible. Should you find an error, or wish to be listed differently, please let us know.